• Pace of cancer drug reimbursement varies wildly across Europe pharmaceutical-technology
    October 22, 2018
    Researchers have found that some European countries take more than twice as long as others to reach health technology assessment (HTA) decisions about reimbursing cancer drugs following European Medicines Agency (EMA) approval.
PharmaSources Customer Service